Smith & Nephew outlines next earnings date, shares in analyst focus

Smith & Nephew is approaching its next half-year report in early August, while London-listed shares trade above 1,100 pence and analysts see meaningful upside potential for the stock.

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 20:07.

Smith & Nephew (US83175M2052) is heading toward its next key reporting date on 4 August 2026, when it plans to publish results for the second quarter and first half of the year, according to its latest trading update and financial calendar. The medical-technology group is listed in London under ticker SN and its shares trade on the LSE, offering international investors exposure to orthopedics and surgical devices.

What recent figures show

In its first-quarter 2026 trading update, Smith & Nephew reported revenue of 1.501 billion US dollars, up 6.6 percent on a reported basis versus the prior year and 3.1 percent on an underlying basis, as disclosed in an April announcement. The company highlighted 4.7 percent underlying revenue growth on an adjusted daily sales basis, with Sports Medicine strength partly offsetting softer US knee implant demand. The Q1 2026 trading update on Investegate provides the detailed figures.

Alongside those numbers, management announced a share buyback program of 500 million US dollars to be executed within twelve months, signaling a continued focus on shareholder returns in parallel with investment in growth. The company also reiterated its forward calendar, including a surgeon expert insights event in London held on 9 June 2026 and the upcoming half-year earnings release on 4 August 2026. The official investor relations site lists these upcoming events.

Analyst expectations for the stock

Consensus data gathered by Investing.com shows that 17 analysts currently cover Smith & Nephew, with an overall rating of "Buy" for the stock. Within this group, 7 analysts recommend buying the shares and 10 advise holding them, while none of the surveyed houses recommend selling at this stage. The consensus overview on Investing.com summarizes these ratings.

The same compilation points to an average 12?month price target of around 1,410.57 pence for the London-listed shares, with individual targets ranging from about 1,204.13 pence on the low end to 1,631.65 pence at the top. Based on the current level, this implies potential upside in the mid?20 percent range, indicating that many analysts still see valuation headroom despite the recent recovery in the share price. MarketBeat’s summary of the stock also reflects a constructive stance.

How Smith & Nephew earns money

Smith & Nephew generates the bulk of its revenue from medical devices for orthopedics, sports medicine and advanced wound management, selling into hospitals and clinics worldwide. Its portfolio includes hip and knee implants, arthroscopy systems for minimally invasive joint surgery, and dressings and negative-pressure systems designed to support wound healing for chronic and acute conditions.

Where the shares trade today

The Smith & Nephew shares (US83175M2052) most actively trade in London under ticker SN on the London Stock Exchange, where they last changed hands at around 1,118 pence on 2026-06-23, 19:00 London time, according to exchange data.

Key data on the Smith & Nephew shares

• Company: Smith & Nephew plc
• ISIN: US83175M2052
• WKN: 881567
• Ticker: SN / SNN
• Trading venue: London Stock Exchange / NASDAQ (ADR)
• Price (as of 2026-06-23, 19:00): 1,118.00 GBX
• Market cap: 12.21 billion GBP (as of 2026-06-22)
• Sector / industry: Health Care / Medical Devices
• Index membership: FTSE 100
• Next earnings date: 2026-08-04

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation, or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.